The Brains Trust, page-14931

Bios. Been buying a few AVH low 8s. First stock purchase in many weeks. This foray into the US is make or break and it's speculative in anyone's language. But the product is proven and approved for use in the numerous burns clinics in the US. Rather than product risk, it's execution risk and maneuvering with the reimbursement system. The company believes they have a financial model that will work for hospitals in terms of pricing. Fully funded for the rollout after raising $40m at 8c. Other risks include liquidity and tranche 2 still to be issued, after shareholder approval.